Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Lancet Infect Dis. 2024 Oct;24(10):1083-1092. doi: 10.1016/S1473-3099(24)00289-5. Epub 2024 May 28. Lancet Infect Dis. 2024. PMID: 38821073 Clinical Trial.
Evaluation of a tailored epilepsy training program for healthcare providers in Uganda.
Arinda A, Ouma S, Kalani K, Ramasubramanian P, Johnson T, Charles A, Newson C, Ratliff O, Kakooza-Mwesige A, Njeru P, Kaddumukasa M, Kaddumukasa M, Kolls B, Husain A, Tchapyjnikov D, Haglund M, Fuller A, Prose N, Koltai D. Arinda A, et al. Epilepsy Behav. 2023 Jan;138:108977. doi: 10.1016/j.yebeh.2022.108977. Epub 2022 Nov 26. Epilepsy Behav. 2023. PMID: 36446268
Differences in Reasons for Late Presentation to HIV Care in Uganda Among Men and Women.
Lofgren SM, Tsui S, Natala N, Nakasujja N, Sebuliba R, Ndyetukira JF, Arinda A, Akinyange V, Hullsiek KH, Nalintya E, Sadiq A, Pastick KA, Stadleman A, Meya D, Boulware DR. Lofgren SM, et al. Among authors: arinda a. AIDS Behav. 2023 Jan;27(1):303-313. doi: 10.1007/s10461-022-03764-9. Epub 2022 Aug 2. AIDS Behav. 2023. PMID: 35916948 Free PMC article.
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20. Lancet HIV. 2022. PMID: 35460601 Free article. Clinical Trial.
Can COVID-19 changes reduce stigma in African HIV clinics?
Lofgren SM, Kigozi J, Natala NG, Tsui S, Arinda A, Akinyange V, Sebuliba R, Boulware DR, Castelnuovo B. Lofgren SM, et al. Among authors: arinda a. Lancet HIV. 2022 May;9(5):e304-e305. doi: 10.1016/S2352-3018(22)00045-5. Epub 2022 Mar 22. Lancet HIV. 2022. PMID: 35334225 Free PMC article. No abstract available.
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Kaimal A, Mirembe G, Tukamushabe P, Ategeka G, Hakim J, Mugerwa H, Siika A, Asienzo J, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. N Engl J Med. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609. N Engl J Med. 2021. PMID: 34289276 Clinical Trial.